ZEISS presents a series of major innovations and industry-first software applications as part of the ZEISS medical ecosystem
“ZEISS continues to invest in digital technologies, taking our digital offerings to the next level with the ZEISS medical ecosystem that helps customers realize the value of a connected environment,” said Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. “Our mission is to contribute to the progress of medicine, by enabling more effective and more cost-effective treatments and by giving access to high quality medical care to as many people as possible. Our investment in digital technology will continue to facilitate the adoption of digitization. and intuitive.”
ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the ZEISS QUATERA 700*. This revolution in phaco technology includes the QUATTRO pump patented by ZEISS® which ensures chamber stability independent of intraocular pressure (IOP) and flow. The QUATERA 700 increases the efficiency of a surgeon’s workflow from the clinic to the operating room, enabling a digitally integrated surgical workflow. “I was looking forward to having this system in my operating room, it was a big moment for me,” said Sri GaneshaMD, President and CEO of Nethradhama Super Specialty Eye Hospital, Bangalore/India. “Then I saw it actually worked – the chamber is so stable, the new pump works great. It’s something I’ve never seen before and I’ve used all the different phaco machines over the of my nearly three-decade career.”
The ZEISS Cataract workflow is further enhanced with two new original surgical software applications. New ZEISS EYE GUIDE* The patient software application is a virtual coach allowing patients and clinics to stay connected throughout the cataract treatment process. the ZEISS Surgery Optimizer* The app is developed for surgeons as a new and innovative way to use surgical videos to enable physician self-education and standardization of surgical techniques.
Moreover, the new ZEISS CT LUCIA 621* The monofocal IOL features the patented ZEISS Optic (ZO) Asphericity concept with its unique forgiving design to deliver excellent visual results for a wide range of patients and surgical situations, and the new ZEISS OPTIKIT* offers a fully customizable surgical package that perfectly complements the ZEISS lens extraction offering.
“Combined with ZEISS’ data platform and surgical planning software, these innovations position ZEISS as a fully-fledged surgical leader in ophthalmology,” said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit at Carl Zeiss Meditec. “Harnessing the power of data-driven insights, ZEISS is creating an environment where connectivity, automation, artificial intelligence, and safe and efficient data management can solve the challenges customers face every day.
New ZEISS VISUMAX 800*the next generation of femtosecond lasers from ZEISS, creates a comfortable experience for both patient and surgeon by reducing laser time and potential transcription errors through simplified treatment planning and data analysis via FORUM® to the ZEISS Refractive Workplace* via a digitally connected corneal refractive workflow.
“I’m sure every surgeon will appreciate the benefits of digital connectivity, such as the elimination of transcription errors and the ability to plan remotely, but the biggest step forward is the incredible speed of the VISUMAX 800 laser scan, which which makes loss of suction virtually a thing of the past,” said Prof. Dr. Walter Sekundo, Professor and Chairman of the Department of Ophthalmology at Philipps University Marburg, Germany.
Additionally, the ZEISS Retina workflow has been enhanced beyond the traditional ophthalmology practice and into primary healthcare settings with the new ZEISS VELARA Teleretinal Screening System, a complete end-to-end solution used by primary care providers to help improve quality and compliance for diabetes patients, enabling annual retinal exams to be performed during routine primary care visits. The solution is initially only available in the United States.
“We always believe that we provide the best medical care available. And so how do we do that in the shortest possible time, how do we get patients in and out?” says dr. Nathan Kiskilageneral practitioner in emergency care, president, founder and co-owner of Marque Medical, California/USA. “The ZEISS VELARA Teleretinal Screening System is one more thing that I think we will have in our toolbox as physicians to offer our patients to really deliver good medical care and make things happen.”
The new integrated devices, software applications and other workflow solutions will be showcased this week during ZEISS Innovation Week September 21 to 23, 2021. For more information, visit www.zeiss.com/med.
*ZEISS QUATERA 700, ZEISS CT LUCIA 621, ZEISS Surgery Optimizer, ZEISS EYEGUIDE, ZEISS OPTIKIT, ZEISS VISUMAX 800 and ZEISS Refractive Workplace are not available for sale or use in certain markets.
Not all products, services or offerings are endorsed or offered in all markets and approved labeling and instructions may vary by country. For country-specific product information, see the appropriate country website. Product specifications may change in design and scope of delivery due to ongoing technical development.
Contact for investors
Investor Relations Director
Carl Zeiss Meditec SA
Telephone: +49 3641 220 116
To post: [email protected]
Contact for the press
Head of Global Communications Ophthalmic Devices
Carl Zeiss Meditec
Telephone: +1 925 719 7825
To post: [email protected]
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the German Stock Exchange MDAX and TecDAX, is one of the world’s leading medical technology companies. The Company provides innovative technologies and application-driven solutions designed to help physicians improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, for diagnosing and treating eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of €1,335.5 million during the 2019/20 financial year (at September 30, 2020).
The Group’s head office is located in Jena, Germanyand has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the United States, Japan, Spain and France. The Center for Application and Research (CARIn) of Bengaluru, India and the Carl Zeiss Innovations Research and Development Center in Shanghai, China, strengthen the Company’s presence in these developing economies. Approximately 41% of the shares of Carl Zeiss Meditec AG are free float. The rest approx. 59% are held by Carl Zeiss AG, one of the world’s leading groups in the optics and optoelectronics industries.
For more information visit: www.zeiss.com/med
SOURCE Carl Zeiss Meditec AG